Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34 + cells in healthy volunteers

Michal Abraham, Yaron Pereg, Baruch Bulvik, Shiri Klein, Inbal Mishalian, Hana Wald, Orly Eizenberg, Katia Beider, Arnon Nagler, Rottem Golan, Abi Vainstein, Arnon Aharon, Eithan Galun, Yoseph Caraco, Reuven Or, Amnon Peled*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Purpose: The potential of the high-affinity CXCR4 antagonist BL-8040 as a monotherapy-mobilizing agent and its derived graft composition and quality were evaluated in a phase I clinical study in healthy volunteers (NCT02073019). Experimental Design: The first part of the study was a randomized, double-blind, placebo-controlled dose escalation phase. The second part of the study was an open-label phase, in which 8 subjects received a single injection of BL-8040 (1 mg/kg) and approximately 4 hours later underwent a standard leukapheresis procedure. The engraftment potential of the purified mobilized CD34 + cells was further evaluated by transplanting the cells into NSG immunodeficient mice. Results: BL-8040 was found safe and well tolerated at all doses tested (0.5–1 mg/kg). The main treatment-related adverse events were mild to moderate. Transient injection site and systemic reactions were mitigated by methylprednisolone, paracetamol, and promethazine pretreatment. In the first part of the study, BL-8040 triggered rapid and substantial mobilization of WBCs and CD34 þ cells in all tested doses. Four hours postdose, the count rose to a mean of 8, 37, 31, and 35 cells/mL (placebo, 0.5, 0.75, and 1 mg/kg, respectively). FACS analysis revealed substantial mobilization of immature dendritic, T, B, and NK cells. In the second part, the mean CD34 + cells/kg collected were 11.6 10 6 cells/kg. The graft composition was rich in immune cells. Conclusions: The current data demonstrate that BL-8040 is a safe and effective monotherapy strategy for the collection of large amounts of CD34 + cells and immune cells in a one-day procedure for allogeneic HSPC transplantation.

Original languageAmerican English
Pages (from-to)6790-6801
Number of pages12
JournalClinical Cancer Research
Issue number22
StatePublished - 15 Nov 2017

Bibliographical note

Publisher Copyright:
©2017 AACR.


Dive into the research topics of 'Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34 + cells in healthy volunteers'. Together they form a unique fingerprint.

Cite this